Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) Versus Docetaxel in Previously Treated Subjects With Non-Small Cell Lung Cancer

Next Previous
X
Search
Trial Profile

A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) Versus Docetaxel in Previously Treated Subjects With Non-Small Cell Lung Cancer

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 21 May 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Docetaxel
  • Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms KEYNOTE-010
  • Sponsors Merck & Co; Merck Sharp & Dohme

    • Most Recent Events

    • 21 May 2022 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information record: JapicCTI132355).
    • 03 Dec 2021 Results of Network Meta-Analyses from CHECKMATE 017, KEYNOTE 010, POPLAR and OAK presented at the 24th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
    • 25 May 2021 Protocol was amended to allow patients in docetaxel group who had disease progression on study or who had started subsequent anticancer therapy following study participation and then experienced disease progression could crossover to pembrolizumab 200 mg Q3W for up to 35 cycles/2 years or until discontinuation criteria were met.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top